Baker Bros. Advisors LP Aurinia Pharmaceuticals Inc. Transaction History

Baker Bros. Advisors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$17.78 - $33.08 $9.25 Million - $17.2 Million	-520,523 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$10.93 - $23.55 $6.55 Million - $14.1 Million	-599,439 Reduced 53.52%	520,523 $11.5 Million
Q2 2021 Aug 16, 2021	SELL	$10.0 - $14.52 $2.9 Million - $4.21 Million	-290,102 Reduced 20.57%	1,119,962 $14.5 Million
Q4 2020 Feb 16, 2021	SELL	$12.94 - $16.05 $2.69 Million - $3.34 Million	-207,965 Reduced 12.85%	1,410,064 $19.5 Million
Q3 2020 Nov 16, 2020	SELL	$13.19 - $16.66 $1.11 Million - $1.4 Million	-83,900 Reduced 4.93%	1,618,029 $23.8 Million

Q4 2019 Feb 14, 2020	BUY	$3.88 - $21.42 $6.6 Million - $36.5 Million	1,701,929 New	1,701,929 $34.5 Million

205

55.6M

838K

1.18M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $810M
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.